Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

    HAE: TSX

    MONTREAL, Oct. 31 /CNW Telbec/ - Haemacure Corporation (TSX:HAE), a
specialty bio-therapeutics company, announces the webcast of its presentation
at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference, on
November 7, 2007 at 11:30 a.m. at the New York Palace Hotel in New York.
    Rodman & Renshaw will webcast the audio portion of the presentation and
post the associated slides via its website at www.rodmanandrenshaw.com, hosted
by Wall Street Webcasting. To access the live broadcast via internet in
listen-only mode, or the subsequently archived recording, please cut and paste
the following link directly into your web browser:


    Please visit the site at least five minutes prior to start time for

    About the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

    The Conference will include presentations by over 375 companies, as well
as experts from the medical, scientific and investment communities. The
Conference will be attended by investors, venture capitalists, company
executives, scientists and other industry leaders. Since 1951, Rodman &
Renshaw has been dedicated to serving the needs of companies in emerging
growth sectors and the investors that seek value in these companies. The
Acumen BioFin division of Rodman & Renshaw is exclusively focused on
healthcare and life science companies. For further information, visit

    About Haemacure

    Haemacure Corporation is a specialty bio-therapeutics company developing
high-value human therapeutic proteins for commercialization. Haemacure's
research and development effort is driven by its proprietary plasma protein
extraction technology to develop next-generation products, including surgical
    Haemacure's lead product candidate, Hemaseel(R)HMN, is a human-derived
fibrin sealant in late-stage clinical development. Haemacure's second product
candidate is human thrombin, a component of its fibrin sealant. Both
candidates have applications in the expanding bio-surgical market. Follow-on
development will focus on surgical hemostats, biomaterial combinations and
drug delivery in select therapeutic areas. Haemacure has recently discovered
additional specialty proteins in its plasma-derived intermediates and will
advance these specialty proteins through partnerships with other
pharmaceutical and biotechnology companies.

    Forward-looking Statements

    Certain statements contained in this news release and oral statements
made by representatives of Haemacure that are not historical facts may be
considered forward-looking statements. Such statements, based as they are on
the current expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
Corporation does business, stock market volatility, fluctuations in costs, the
ability of Haemacure to set up its planned manufacturing facility, the
completion and outcome of clinical studies as well as the development of new
products, and changes to the competitive environment due to consolidation or
otherwise. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. Haemacure
Corporation disclaims any intention or obligation to update these statements.

For further information:

For further information: Joseph Galli, Chairman and CEO, Haemacure
Corporation, (514) 990-7074, jgalli@haemacure.ca, www.haemacure.com; Gilles
Lemieux, Investor Relations, Haemacure Corporation, (514) 282-3350 ext. 22,
glemieux@haemacure.ca, www.haemacure.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890